NASDAQ:ALNY - Alnylam Pharmaceuticals Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $172.07
Forecasted Upside: 4.27 %
Number of Analysts: 15
Breakdown:
0 Sell Ratings
7 Hold Ratings
8 Buy Ratings
0 Strong Buy Ratings

^$165.02 As of 06/11/2021 01:00 AM ET

▲ +1.76 (1.08%)

1 month | 3 months | 12 months

Get New Alnylam Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ALNY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALNY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$172.07

▲ +4.27% Upside Potential

This price target is based on 15 analysts offering 12 month price targets for Alnylam Pharmaceuticals in the last 3 months. The average price target is $172.07, with a high forecast of $235.00 and a low forecast of $91.00. The average price target represents a 4.27% upside from the last price of $165.02.

Buy

The current consensus among 15 contributing investment analysts is to buy stock in Alnylam Pharmaceuticals. This rating has held steady since April 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
10 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

12/21/2019

0 strong buy ratings
11 buy ratings
6 hold ratings
1 sell ratings

Ratings as of

3/20/2020

0 strong buy ratings
11 buy ratings
6 hold ratings
1 sell ratings

Ratings as of

6/18/2020

0 strong buy ratings
11 buy ratings
8 hold ratings
1 sell ratings

Ratings as of

9/16/2020

0 strong buy ratings
11 buy ratings
8 hold ratings
1 sell ratings

Ratings as of

12/15/2020

0 strong buy ratings
9 buy ratings
9 hold ratings
1 sell ratings

Ratings as of

3/15/2021

0 strong buy ratings
8 buy ratings
8 hold ratings
0 sell ratings

Ratings as of

5/14/2021

0 strong buy ratings
8 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

6/13/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
4/30/2021	Morgan Stanley	Lower Price Target	Overweight	$206.00 ➝ $205.00	Low	i
4/20/2021	Needham & Company LLC	Reiterated Rating	Buy		Low	i
3/1/2021	Guggenheim	Reiterated Rating	Buy ➝ Neutral	$162.00	Low	i
2/22/2021	Guggenheim	Downgrade	Buy ➝ Neutral	$162.00	Medium	i
2/14/2021	Royal Bank of Canada	Reiterated Rating	Hold		Low	i
2/12/2021	Needham & Company LLC	Boost Price Target	Buy	$160.00 ➝ $180.00	Low	i
2/12/2021	Morgan Stanley	Boost Price Target	Overweight	$203.00 ➝ $206.00	Low	i
2/12/2021	Citigroup	Downgrade	Buy ➝ Neutral	$170.00 ➝ $175.00	Low	i
2/12/2021	Barclays	Boost Price Target	Overweight	$162.00 ➝ $196.00	Low	i
2/12/2021	HC Wainwright	Boost Price Target	Buy	$225.00 ➝ $235.00	Low	i Rating by P. Trucchio at HC Wainwright
1/25/2021	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$185.00 ➝ $185.00	High	i
1/13/2021	Cowen	Boost Price Target	In-Line ➝ Outperform	$154.00 ➝ $197.00	High	i
1/8/2021	HC Wainwright	Reiterated Rating	Buy	$225.00	High	i Rating by P. Trucchio at HC Wainwright
12/21/2020	Royal Bank of Canada	Lower Price Target	Sector Perform	$150.00 ➝ $144.00	Medium	i
12/17/2020	Piper Sandler	Boost Price Target	Overweight	$169.00 ➝ $181.00	Low	i
11/25/2020	BMO Capital Markets	Boost Price Target		$182.00 ➝ $183.00	Low	i
11/25/2020	Morgan Stanley	Boost Price Target	Overweight	$200.00 ➝ $203.00	Low	i
11/24/2020	SVB Leerink	Boost Price Target	Market Perform	$90.00 ➝ $91.00	Low	i
11/6/2020	Morgan Stanley	Boost Price Target	Overweight	$197.00 ➝ $200.00	High	i
10/15/2020	Bank of America	Lower Price Target	Buy	$160.00 ➝ $157.00	Low	i
10/12/2020	Chardan Capital	Reiterated Rating	Buy		Low	i
9/30/2020	Oppenheimer	Reiterated Rating	Hold	$156.00	Medium	i Rating by Leland Gershell at Oppenheimer Holdings Inc.
9/30/2020	Berenberg Bank	Initiated Coverage	Hold	$145.00	Medium	i
9/8/2020	Citigroup	Initiated Coverage	Buy	$170.00 ➝ $170.00	Low	i
8/24/2020	HC Wainwright	Reiterated Rating	Buy		Low	i Rating by P. Trucchio at HC Wainwright
8/11/2020	Oppenheimer	Downgrade	Outperform ➝ Market Perform	$162.00 ➝ $156.00	Low	i Rating by Leland Gershell at Oppenheimer Holdings Inc.
8/7/2020	Morgan Stanley	Lower Price Target	Overweight	$199.00 ➝ $197.00	Low	i
8/7/2020	Chardan Capital	Reiterated Rating	Buy		Low	i
8/7/2020	SVB Leerink	Boost Price Target	Market Perform	$89.00 ➝ $90.00	Low	i
7/20/2020	BMO Capital Markets	Boost Price Target	Outperform	$173.00 ➝ $196.00	High	i
7/15/2020	Morgan Stanley	Boost Price Target	Overweight	$162.00 ➝ $199.00	Low	i
5/28/2020	UBS Group	Boost Price Target	Neutral	$111.00 ➝ $122.00	Low	i
5/12/2020	Royal Bank of Canada	Initiated Coverage	Sector Perform	$150.00	Medium	i
5/7/2020	BMO Capital Markets	Boost Price Target	Outperform	$145.00 ➝ $171.00	Low	i
5/7/2020	Oppenheimer	Boost Price Target	Outperform	$140.00 ➝ $162.00	High	i Rating by Leland Gershell at Oppenheimer Holdings Inc.
5/7/2020	Morgan Stanley	Boost Price Target	Overweight	$148.00 ➝ $162.00	High	i
5/7/2020	Barclays	Boost Price Target	Overweight	$143.00 ➝ $156.00	High	i
5/7/2020	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$133.00 ➝ $137.00	High	i
5/6/2020	Needham & Company LLC	Boost Price Target	Buy	$135.00 ➝ $160.00	High	i Rating by Alan Carr at Needham & Company LLC
4/24/2020	Evercore ISI	Initiated Coverage	Buy	$160.00	Low	i Rating by Maneka Mirchandaney at Evercore ISI
4/14/2020	Needham & Company LLC	Reiterated Rating	Buy	$135.00	High	i Rating by Alan Carr at Needham & Company LLC
4/14/2020	Cantor Fitzgerald	Boost Price Target		$195.00 ➝ $202.00	Low	i Rating by Alethia Young at Cantor Fitzgerald
4/14/2020	Piper Sandler	Lower Price Target		$147.00 ➝ $142.00	Medium	i Rating by Edward Tenthoff at Piper Sandler
4/14/2020	Nomura Securities	Lower Price Target	Reduce	$75.00 ➝ $74.00	Medium	i
4/13/2020	Oppenheimer	Reiterated Rating	Buy	$140.00	Medium	i Rating by Leland Gershell at Oppenheimer Holdings Inc.
3/19/2020	Berenberg Bank	Initiated Coverage	Buy	$200.00	Low	i
3/5/2020	Cowen	Reiterated Rating	Buy		Medium	i
3/3/2020	Piper Sandler	Reiterated Rating	Buy	$155.00	N/A	i Rating by Edward Tenthoff at Piper Sandler
2/11/2020	Nomura Securities	Boost Price Target	Reduce	$62.00 ➝ $75.00	Medium	i Rating by Christopher Marai at Nomura Securities
2/9/2020	Cowen	Reiterated Rating	Buy	$154.00	High	i
2/7/2020	Evercore ISI	Initiated Coverage	Buy	$145.00	High	i Rating by Maneka Mirchandaney at Evercore ISI
2/7/2020	Morgan Stanley	Lower Price Target	Overweight	$150.00 ➝ $148.00	Medium	i
2/7/2020	Chardan Capital	Reiterated Rating	Buy		High	i
2/7/2020	Needham & Company LLC	Reiterated Rating	Buy		High	i Rating by Alan Carr at Needham & Company LLC
12/19/2019	Chardan Capital	Boost Price Target	Buy	$150.00 ➝ $190.00	Low	i
12/18/2019	Nomura Securities	Reiterated Rating	Sell	$62.00	Low	i Rating by Christopher Marai at Nomura Securities
12/18/2019	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$159.00 ➝ $176.00	Medium	i Rating by Alethia Young at Cantor Fitzgerald
12/17/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$145.00 ➝ $155.00	Medium	i Rating by Edward Tenthoff at Piper Jaffray Companies
12/17/2019	Morgan Stanley	Boost Price Target	Overweight	$141.00 ➝ $150.00	High	i
11/27/2019	Cantor Fitzgerald	Boost Price Target		$150.00 ➝ $159.00	Low	i Rating by Alethia Young at Cantor Fitzgerald
11/21/2019	BMO Capital Markets	Boost Price Target	Outperform	$128.00 ➝ $138.00	High	i
11/21/2019	Barclays	Boost Price Target	Overweight	$125.00 ➝ $131.00	High	i
11/21/2019	Needham & Company LLC	Initiated Coverage	Buy	$135.00	Low	i Rating by Alan Carr at Needham & Company LLC
11/21/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$150.00 ➝ $159.00	Low	i Rating by Alethia Young at Cantor Fitzgerald
11/19/2019	Oppenheimer	Initiated Coverage	Outperform	$128.00 ➝ $128.00	High	i
11/18/2019	Cowen	Reiterated Rating	Buy	$120.00	High	i
11/13/2019	Bank of America	Initiated Coverage	Buy	$110.00	Low	i
10/31/2019	Needham & Company LLC	Reiterated Rating	Buy	$135.00	Low	i
10/8/2019	Nomura Securities	Set Price Target	Sell	$62.00	Low	i Rating by Christopher Marai at Nomura Securities
9/10/2019	Piper Jaffray Companies	Set Price Target	Buy	$145.00	High	i Rating by Edward Tenthoff at Piper Jaffray Companies
9/4/2019	UBS Group	Boost Price Target	Neutral	$95.00 ➝ $96.00	Low	i
9/3/2019	Stifel Nicolaus	Set Price Target	Buy	$116.00	Low	i Rating by Paul Matteis at Stifel Nicolaus
9/3/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$142.00 ➝ $145.00	Medium	i Rating by Edward Tenthoff at Piper Jaffray Companies
8/26/2019	Piper Jaffray Companies	Set Price Target	Buy	$142.00	Low	i Rating by Edward Tenthoff at Piper Jaffray Companies
8/7/2019	Barclays	Reiterated Rating	Buy	$125.00	High	i
8/7/2019	Morgan Stanley	Lower Price Target	Overweight	$126.00 ➝ $124.00	High	i Rating by David Lebovitz at Morgan Stanley
8/7/2019	Cowen	Lower Price Target	Outperform	$147.00 ➝ $120.00	High	i
5/23/2019	The Goldman Sachs Group	Reiterated Rating	Neutral ➝ Neutral	$80.00	Medium	i
5/2/2019	Morgan Stanley	Set Price Target	Buy	$126.00	High	i Rating by David Lebovitz at Morgan Stanley
5/2/2019	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$126.00 ➝ $128.00	High	i
4/15/2019	Stifel Nicolaus	Boost Price Target	Buy ➝ Buy	$110.00 ➝ $116.00	Low	i
4/15/2019	Cantor Fitzgerald	Boost Price Target	Overweight ➝ Overweight	$135.00 ➝ $138.00	Low	i
4/15/2019	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$119.00 ➝ $126.00	Low	i
4/11/2019	Evercore ISI	Initiated Coverage	Outperform	$120.00	Medium	i
4/9/2019	SVB Leerink	Boost Price Target	Market Perform	$90.00	Medium	i Rating by M. Foroohar at SVB Leerink LLC
4/9/2019	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$106.00 ➝ $119.00	High	i
4/9/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$135.00	Medium	i
4/9/2019	Chardan Capital	Reiterated Rating	Buy	$150.00	Medium	i
3/6/2019	Cowen	Reiterated Rating	Buy		Low	i
3/6/2019	Evercore ISI	Upgrade	In-Line ➝ Outperform		Low	i
3/5/2019	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$122.00	Low	i
2/8/2019	Needham & Company LLC	Reiterated Rating	Buy	$135.00	High	i Rating by Alan Carr at Needham & Company LLC
2/8/2019	BMO Capital Markets	Lower Price Target	Outperform	$106.00	High	i
2/7/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$135.00	High	i
1/23/2019	UBS Group	Initiated Coverage	Neutral ➝ Neutral	$87.00	Low	i
1/15/2019	Piper Jaffray Companies	Lower Price Target	Overweight	$152.00	Low	i
12/17/2018	Guggenheim	Initiated Coverage	Buy	$105.00	Medium	i Rating by Whitney Ijem at Guggenheim
12/7/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$135.00	High	i
11/27/2018	SVB Leerink	Initiated Coverage	Market Perform	$63.00	Low	i Rating by M. Foroohar at SVB Leerink LLC
11/8/2018	Cantor Fitzgerald	Reiterated Rating	Buy		N/A	i
10/18/2018	BMO Capital Markets	Reiterated Rating	Buy		High	i
10/16/2018	BMO Capital Markets	Lower Price Target	Outperform ➝ Outperform	$125.00 ➝ $124.00	Medium	i
10/1/2018	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$135.00	Low	i
9/28/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$93.00 ➝ $87.00	High	i Rating by David Lebovitz at Morgan Stanley
9/13/2018	Needham & Company LLC	Reiterated Rating	Buy	$152.00	Medium	i Rating by Alan Carr at Needham & Company LLC
9/13/2018	Stifel Nicolaus	Reiterated Rating	Buy	$123.00 ➝ $117.00	Medium	i
9/4/2018	Cowen	Reiterated Rating	Buy	$147.00	High	i
8/28/2018	JMP Securities	Set Price Target	Buy	$198.00	Medium	i Rating by Konstantinos Aprilakis at JMP Securities
8/27/2018	Needham & Company LLC	Set Price Target	Buy	$152.00	Low	i Rating by Alan Carr at Needham & Company LLC
8/13/2018	B. Riley	Boost Price Target	Buy ➝ Buy	$210.00 ➝ $230.00	High	i
8/13/2018	Nomura Securities	Lower Price Target	Reduce ➝ Reduce	$86.00 ➝ $73.00	High	i
8/13/2018	Morgan Stanley	Set Price Target	Equal Weight ➝ Hold	$99.00 ➝ $93.00	High	i Rating by David Lebovitz at Morgan Stanley
8/13/2018	Needham & Company LLC	Reiterated Rating	Buy	$152.00	High	i
8/13/2018	Cowen	Lower Price Target	Outperform ➝ Outperform	$157.00 ➝ $147.00	High	i
8/13/2018	Stifel Nicolaus	Reiterated Rating	Sell ➝ Buy	$125.00 ➝ $123.00	Medium	i
8/13/2018	The Goldman Sachs Group	Downgrade	Conviction-Buy ➝ Buy		Low	i
8/13/2018	BMO Capital Markets	Lower Price Target	Outperform ➝ Outperform	$127.00 ➝ $125.00	High	i
8/6/2018	Stifel Nicolaus	Upgrade	Hold ➝ Buy	$95.00 ➝ $125.00	Low	i
8/6/2018	Jefferies Financial Group	Reiterated Rating	Buy	$149.00	Low	i Rating by Maury Raycroft at Jefferies Financial Group Inc.
8/6/2018	JMP Securities	Set Price Target	Buy	$207.00	Medium	i Rating by Konstantinos Aprilakis at JMP Securities
8/3/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$107.00 ➝ $99.00	High	i
8/3/2018	Chardan Capital	Reiterated Rating	Buy	$180.00	High	i
8/3/2018	BMO Capital Markets	Reiterated Rating	Buy	$127.00	High	i
8/2/2018	Cowen	Reiterated Rating	Buy	$157.00	High	i
7/23/2018	Piper Jaffray Companies	Reiterated Rating	Overweight		Low	i
6/27/2018	Piper Jaffray Companies	Lower Price Target	Overweight	$182.00 ➝ $160.00	Medium	i
5/7/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$118.00	Medium	i
5/4/2018	BMO Capital Markets	Lower Price Target	Outperform ➝ Outperform	$160.00 ➝ $134.00	N/A	i
5/4/2018	Stifel Nicolaus	Lower Price Target	Hold ➝ Hold	$107.00 ➝ $95.00	High	i
4/2/2018	B. Riley	Reiterated Rating	Buy	$200.00	Medium	i Rating by M. Kumar at B. Riley
4/2/2018	Jefferies Financial Group	Reiterated Rating	Buy		High	i Rating by Maury Raycroft at Jefferies Financial Group Inc.
3/28/2018	Evercore ISI	Initiated Coverage	In ➝ line	$131.18 ➝ $143.00	Medium	i
3/26/2018	JMP Securities	Boost Price Target	Mkt Outperform ➝ Outperform	$169.00 ➝ $207.00	Low	i
3/13/2018	Credit Suisse Group	Boost Price Target	Outperform ➝ Outperform	$151.00 ➝ $154.00	High	i Rating by Alethia Young at Credit Suisse Group AG
2/16/2018	B. Riley	Lower Price Target	Buy ➝ Buy	$205.00 ➝ $200.00	Medium	i Rating by M. Kumar at B. Riley
2/9/2018	Credit Suisse Group	Set Price Target	Buy	$151.00	Low	i Rating by Alethia Young at Credit Suisse Group AG
2/9/2018	Jefferies Financial Group	Set Price Target	Buy	$156.00	Low	i Rating by Eun Yang at Jefferies Financial Group Inc.
2/9/2018	Nomura Securities	Boost Price Target	Sell	$86.00	Low	i
2/9/2018	BMO Capital Markets	Lower Price Target	Outperform ➝ Outperform	$165.00 ➝ $160.00	Medium	i
2/9/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$128.00 ➝ $118.00	Medium	i
1/25/2018	SVB Leerink	Boost Price Target	Market Perform ➝ Market Perform	$132.00 ➝ $135.00	Low	i
1/19/2018	B. Riley	Reiterated Rating	Buy	$205.00	Low	i Rating by M. Kumar at B. Riley
1/19/2018	Chardan Capital	Reiterated Rating	Buy		Low	i Rating by G. Amusa at Chardan Capital
1/8/2018	B. Riley	Reiterated Rating	Buy ➝ Buy	$220.00 ➝ $205.00	Medium	i Rating by M. Kumar at B. Riley
1/7/2018	Piper Jaffray Companies	Reiterated Rating	Buy	$182.00	Medium	i
12/15/2017	The Goldman Sachs Group	Upgrade	Buy ➝ Conviction-Buy		High	i
12/11/2017	B. Riley	Reiterated Rating	Buy	$220.00	Low	i Rating by M. Kumar at B. Riley
11/17/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$182.00	N/A	i Rating by Edward Tenthoff at Piper Jaffray Companies
11/9/2017	Cowen	Reiterated Rating	Buy	$151.00	N/A	i
11/9/2017	Morgan Stanley	Boost Price Target	Equal Weight	$101.00 ➝ $130.00	N/A	i
11/9/2017	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight		N/A	i Rating by Anupam Rama at JPMorgan Chase & Co.
11/8/2017	B. Riley	Lower Price Target	Buy	$220.00	N/A	i Rating by M. Kumar at B. Riley
11/8/2017	Barclays	Boost Price Target	Overweight	$127.00 ➝ $158.00	N/A	i
11/3/2017	Credit Suisse Group	Boost Price Target	Outperform	$123.00 ➝ $151.00	N/A	i Rating by Alethia Young at Credit Suisse Group AG
11/3/2017	Cowen	Reiterated Rating	Outperform	$117.00 ➝ $151.00	N/A	i
11/3/2017	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $152.00	N/A	i
11/2/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$188.00 ➝ $14.71	N/A	i Rating by Edward Tenthoff at Piper Jaffray Companies
11/1/2017	B. Riley	Initiated Coverage	Buy	$150.00 ➝ $240.00	N/A	i Rating by M. Kumar at B. Riley
10/30/2017	(FBRC)	Initiated Coverage	Buy ➝ Buy	$150.00	N/A	i Rating by M. Kumar at (FBRC)
10/2/2017	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$62.00 ➝ $163.00	Medium	i
9/26/2017	Jefferies Financial Group	Boost Price Target	Positive ➝ Buy	$102.00 ➝ $130.00	Low	i Rating by Eun Yang at Jefferies Financial Group Inc.
9/25/2017	Chardan Capital	Reiterated Rating	Buy	$124.00	Low	i Rating by G. Amusa at Chardan Capital
9/22/2017	BMO Capital Markets	Reiterated Rating	Outperform	$99.00 ➝ $134.00	Low	i
9/21/2017	LADENBURG THALM/SH SH	Reiterated Rating	Buy	$90.00 ➝ $146.00	Low	i Rating by Christopher James at LADENBURG THALM/SH SH
9/21/2017	Sanford C. Bernstein	Reiterated Rating	Outperform ➝ Buy	$94.00 ➝ $135.00	Low	i
9/20/2017	Stifel Nicolaus	Reiterated Rating	Hold	$56.00 ➝ $83.00	Low	i
9/20/2017	Cowen	Reiterated Rating	Outperform	$93.00 ➝ $117.00	Low	i
9/20/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$110.00 ➝ $116.00	Low	i Rating by Edward Tenthoff at Piper Jaffray Companies
9/20/2017	Needham & Company LLC	Boost Price Target	Buy ➝ Buy	$85.00 ➝ $125.00	Low	i
9/20/2017	JMP Securities	Boost Price Target	Outperform	$101.00 ➝ $128.00	Low	i
9/18/2017	Jefferies Financial Group	Reiterated Rating	Buy	$102.00	Low	i Rating by Eun Yang at Jefferies Financial Group Inc.
9/15/2017	Nomura Instinet	Initiated Coverage	Reduce ➝ Reduce	$56.00	Low	i
9/14/2017	Nomura Securities	Initiated Coverage	Reduce	$56.00	High	i
9/11/2017	Chardan Capital	Reiterated Rating	Buy		High	i Rating by Madhu Kumar at Chardan Capital
9/8/2017	SVB Leerink	Reiterated Rating	Market Perform	$83.00 ➝ $72.00	Low	i
9/7/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$126.00 ➝ $110.00	Low	i Rating by Edward Tenthoff at Piper Jaffray Companies
9/7/2017	Needham & Company LLC	Reiterated Rating	Buy	$98.00 ➝ $85.00	Low	i
9/7/2017	Barclays	Reiterated Rating	Equal Weight ➝ Overweight	$80.00 ➝ $105.00	High	i
9/6/2017	BMO Capital Markets	Reiterated Rating	Outperform	$105.00 ➝ $99.00	Low	i
8/25/2017	Jefferies Financial Group	Set Price Target	Buy	$102.00	Low	i
8/11/2017	Credit Suisse Group	Reiterated Rating	Buy	$96.00	Low	i Rating by Alethia Young at Credit Suisse Group AG
8/10/2017	Stifel Nicolaus	Reiterated Rating	Buy	$47.00 ➝ $56.00	Medium	i
8/10/2017	Chardan Capital	Reiterated Rating	Buy	$131.00 ➝ $124.00	Medium	i Rating by Madhu Kumar at Chardan Capital
8/10/2017	Morgan Stanley	Boost Price Target	Equal Weight	$46.00 ➝ $50.00	Medium	i
8/10/2017	Barclays	Boost Price Target	Equal Weight	$50.00 ➝ $70.00	High	i
7/27/2017	Sanford C. Bernstein	Initiated Coverage	Outperform	$99.00	High	i
7/17/2017	LADENBURG THALM/SH SH	Set Price Target	Buy ➝ Buy	$80.00 ➝ $90.00	Low	i Rating by Christopher James at LADENBURG THALM/SH SH
7/11/2017	Cowen	Reiterated Rating	Buy	$100.00	Low	i
7/11/2017	Credit Suisse Group	Set Price Target	Buy	$96.00	Low	i Rating by Alethia Young at Credit Suisse Group AG
7/10/2017	Morgan Stanley	Reiterated Rating	Equal Weight		Low	i
7/10/2017	Needham & Company LLC	Reiterated Rating	Buy	$98.00	Low	i
7/10/2017	Chardan Capital	Reiterated Rating	Buy	$110.00 ➝ $131.00	High	i Rating by Madhu Kumar at Chardan Capital
6/27/2017	Credit Suisse Group	Boost Price Target	Outperform	$90.00 ➝ $96.00	High	i Rating by Alethia Young at Credit Suisse Group AG
6/27/2017	Needham & Company LLC	Boost Price Target	Buy	$68.00 ➝ $98.00	High	i
6/26/2017	JPMorgan Chase & Co.	Reiterated Rating	Hold		N/A	i Rating by Anupam Rama at JPMorgan Chase & Co.
6/22/2017	Jefferies Financial Group	Reiterated Rating	Buy ➝ Buy	$102.00	Low	i
6/21/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$116.00 ➝ $126.00	Low	i Rating by Edward Tenthoff at Piper Jaffray Companies
6/12/2017	Chardan Capital	Set Price Target	Buy	$110.00	Low	i Rating by Madhu Kumar at Chardan Capital
6/2/2017	Janney Montgomery Scott	Initiated Coverage	Underperform ➝ Sell	$69.70 ➝ $67.00	Low	i
5/24/2017	Piper Jaffray Companies	Set Price Target	Buy	$116.00	Low	i Rating by Edward Tenthoff at Piper Jaffray Companies
5/17/2017	LADENBURG THALM/SH SH	Set Price Target	Buy	$75.00 ➝ $80.00	Medium	i Rating by Christopher James at LADENBURG THALM/SH SH
5/17/2017	The Goldman Sachs Group	Reiterated Rating	Neutral	$44.00 ➝ $64.00	Medium	i
5/17/2017	Credit Suisse Group	Reiterated Rating	Outperform	$50.00 ➝ $90.00	Medium	i Rating by Alethia Young at Credit Suisse Group AG
5/17/2017	SVB Leerink	Reiterated Rating	Market Perform	$53.00 ➝ $67.00	High	i
5/17/2017	Cowen	Reiterated Rating	Outperform	$100.00	Low	i
5/15/2017	Piper Jaffray Companies	Set Price Target	Buy	$118.00	High	i Rating by Edward Tenthoff at Piper Jaffray Companies
5/15/2017	Chardan Capital	Lower Price Target	Buy	$110.00 ➝ $95.00	High	i Rating by Madhu Kumar at Chardan Capital
5/9/2017	Credit Suisse Group	Reiterated Rating	Hold	$50.00	Medium	i Rating by Alethia Young at Credit Suisse Group AG
5/8/2017	Morgan Stanley	Boost Price Target	Equal Weight	$39.00 ➝ $42.00	Low	i
5/5/2017	Chardan Capital	Set Price Target	Buy	$97.00 ➝ $95.00	Low	i Rating by Madhu Kumar at Chardan Capital
4/17/2017	BMO Capital Markets	Initiated Coverage	Outperform	$73.00	Medium	i
3/29/2017	UBS Group	Initiated Coverage	Neutral ➝ Neutral	$55.00	N/A	i
3/20/2017	Credit Suisse Group	Downgrade	Hold	$50.00	Medium	i Rating by Alethia Young at Credit Suisse Group AG
3/20/2017	(FBRC)	Reiterated Rating	Buy		High	i Rating by R. Jasuja at (FBRC)
3/7/2017	(FBRC)	Reiterated Rating	Outperform		Low	i Rating by R. Jasuja at (FBRC)
2/9/2017	Needham & Company LLC	Reiterated Rating	Buy	$98.00 ➝ $68.00	N/A	i
2/3/2017	JMP Securities	Set Price Target	Buy	$69.00	N/A	i Rating by Michael King at JMP Securities
2/2/2017	LADENBURG THALM/SH SH	Initiated Coverage	Buy	$75.00	N/A	i
1/9/2017	Chardan Capital	Boost Price Target	Buy	$69.00 ➝ $97.00	N/A	i Rating by Madhu Kumar at Chardan Capital
12/25/2016	Credit Suisse Group	Set Price Target	Buy	$50.00	N/A	i Rating by Alethia Young at Credit Suisse Group AG
12/20/2016	Needham & Company LLC	Reiterated Rating	Buy	$98.00	N/A	i
12/19/2016	Chardan Capital	Lower Price Target	Buy	$89.00 ➝ $69.00	N/A	i
12/6/2016	Needham & Company LLC	Reiterated Rating	Buy		N/A	i Rating by Alan Carr at Needham & Company LLC
12/5/2016	Chardan Capital	Reiterated Rating	Positive	$89.00	N/A	i
12/1/2016	Jefferies Financial Group	Set Price Target	Buy	$58.00	N/A	i Rating by Gena Wang at Jefferies Financial Group Inc.
11/30/2016	Chardan Capital	Boost Price Target	Buy	$73.00 ➝ $89.00	N/A	i
11/24/2016	Jefferies Financial Group	Set Price Target	Buy	$58.00	N/A	i Rating by Gena Wang at Jefferies Financial Group Inc.
11/16/2016	Needham & Company LLC	Reiterated Rating	Buy	$137.00 ➝ $98.00	N/A	i Rating by Alan Carr at Needham & Company LLC
11/10/2016	SVB Leerink	Reiterated Rating	Market Perform	$43.00	N/A	i Rating by M. Schmidt at SVB Leerink LLC
11/7/2016	Credit Suisse Group	Reiterated Rating	Buy	$50.00	N/A	i Rating by Alethia Young at Credit Suisse Group AG
11/3/2016	(FBRC)	Reiterated Rating	Buy	$100.00	N/A	i Rating by Christopher James at (FBRC)
11/3/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Ritu Baral at Cowen Inc
11/3/2016	Barclays	Reiterated Rating	Hold	$50.00	N/A	i
10/24/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$106.00	N/A	i Rating by Edward Tenthoff at Piper Jaffray Companies
10/8/2016	Cowen	Reiterated Rating	Outperform	$150.00 ➝ $100.00	N/A	i Rating by Ritu Baral at Cowen Inc
10/7/2016	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$38.00 ➝ $36.00	N/A	i Rating by matthew harrison at Morgan Stanley
10/6/2016	Piper Jaffray Companies	Set Price Target	Buy	$106.00	N/A	i Rating by Edward Tenthoff at Piper Jaffray Companies
10/6/2016	(FBRC)	Lower Price Target	Outperform	$180.00 ➝ $100.00	N/A	i Rating by christopher james at (FBRC)
10/6/2016	The Goldman Sachs Group	Lower Price Target	Neutral	$65.00 ➝ $34.00	N/A	i
10/6/2016	Stifel Nicolaus	Lower Price Target	Hold	$68.00 ➝ $36.00	N/A	i
10/6/2016	Jefferies Financial Group	Lower Price Target	Buy	$86.00 ➝ $58.00	N/A	i Rating by Gena Wang at Jefferies Financial Group Inc.
10/6/2016	Needham & Company LLC	Downgrade	Buy	$152.00 ➝ $137.00	N/A	i Rating by Alan Carr at Needham & Company LLC
10/6/2016	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$83.00 ➝ $51.00	N/A	i
10/6/2016	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$107.00 ➝ $40.00	N/A	i Rating by Michael Schmidt at SVB Leerink LLC
10/6/2016	Barclays	Downgrade	Overweight ➝ Equal Weight	$85.00 ➝ $50.00	N/A	i
9/30/2016	Credit Suisse Group	Set Price Target	Buy	$145.00	N/A	i Rating by Alethia Young at Credit Suisse Group AG
9/28/2016	Jefferies Financial Group	Set Price Target	Buy	$86.00	N/A	i Rating by Gena Wang at Jefferies Financial Group Inc.
9/28/2016	Janney Montgomery Scott	Initiated Coverage	Neutral	$74.00	N/A	i
9/27/2016	(FBRC)	Reiterated Rating	Outperform	$180.00	N/A	i Rating by christopher james at (FBRC)
9/26/2016	SVB Leerink	Reiterated Rating	Buy		N/A	i Rating by Michael Schmidt at SVB Leerink LLC
9/8/2016	(FBRC)	Reiterated Rating	Buy		N/A	i Rating by christopher james at (FBRC)
9/6/2016	Morgan Stanley	Set Price Target	Buy	$93.00	N/A	i Rating by matthew harrison at Morgan Stanley
8/10/2016	The Goldman Sachs Group	Reiterated Rating	Neutral	$63.00 ➝ $65.00	N/A	i
8/7/2016	Cowen	Reiterated Rating	Buy	$150.00	N/A	i Rating by Ritu Baral at Cowen Inc
8/5/2016	Needham & Company LLC	Reiterated Rating	Buy	$152.00	N/A	i Rating by Alan Carr at Needham & Company LLC
8/5/2016	JPMorgan Chase & Co.	Boost Price Target	Overweight	$80.00 ➝ $83.00	N/A	i Rating by Anupam Rama at JPMorgan Chase & Co.
8/5/2016	Jefferies Financial Group	Boost Price Target	Buy	$80.00 ➝ $86.00	N/A	i Rating by Gena Wang at Jefferies Financial Group Inc.
8/2/2016	Morgan Stanley	Initiated Coverage	Overweight	$93.00	N/A	i
7/25/2016	Needham & Company LLC	Reiterated Rating	Buy	$152.00	N/A	i Rating by Alan Carr at Needham & Company LLC
7/19/2016	SVB Leerink	Reiterated Rating	Buy		N/A	i Rating by Michael Schmidt at SVB Leerink LLC
7/17/2016	(FBRC)	Reiterated Rating	Outperform	$180.00	N/A	i Rating by Christopher James at (FBRC)
7/11/2016	Chardan Capital	Reiterated Rating	Buy		N/A	i
7/10/2016	JMP Securities	Reiterated Rating	Buy		N/A	i
7/5/2016	Cowen	Reiterated Rating	Buy	$150.00	N/A	i Rating by Ritu Baral at Cowen Inc
7/5/2016	(FBRC)	Reiterated Rating	Outperform	$180.00	N/A	i Rating by Christopher James at (FBRC)
7/1/2016	Needham & Company LLC	Reiterated Rating	Buy	$152.00	N/A	i Rating by Alan Carr at Needham & Company LLC
6/30/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i Rating by Gena Wang at Jefferies Financial Group Inc.
6/23/2016	JMP Securities	Reiterated Rating	Buy	$127.00	N/A	i

(Data available from 6/14/2016 forward)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG to develop, manufacture, and commercialize RNAi therapeutics for the treatment of proprotein convertase subtilisin/kexin type 9, hypercholesterolemia, and other human diseases; with Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics to treat SARS-CoV-2, the virus that causes the disease COVID-19; Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease; and with Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $165.02

$161.76

$165.33

50 Day Range

MA: $140.10

$128.63

$165.02

52 Week Range

Now: $165.02

$119.29

$178.41

Volume

712,500 shs

Average Volume

621,015 shs

Market Capitalization

$19.40 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Alnylam Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Alnylam Pharmaceuticals in the last year: Bank of America Co., Barclays PLC, Berenberg Bank, BMO Capital Markets, Chardan Capital, Citigroup Inc., Cowen Inc, Guggenheim, HC Wainwright, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, and SVB Leerink LLC.
View the latest analyst ratings for ALNY.

What is the current price target for Alnylam Pharmaceuticals?

14 Wall Street analysts have set twelve-month price targets for Alnylam Pharmaceuticals in the last year. Their average twelve-month price target is $172.07, suggesting a possible upside of 4.3%. HC Wainwright has the highest price target set, predicting ALNY will reach $235.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $91.00 for Alnylam Pharmaceuticals in the next year.
View the latest price targets for ALNY.

What is the current consensus analyst rating for Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals currently has 7 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ALNY will outperform the market and that investors should add to their positions of Alnylam Pharmaceuticals.
View the latest ratings for ALNY.

What other companies compete with Alnylam Pharmaceuticals?

Other companies that are similar to Alnylam Pharmaceuticals include Amgen, Gilead Sciences, Biogen, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Alexion Pharmaceuticals, Seagen, Exact Sciences, Incyte, Novavax, BioMarin Pharmaceutical, Repligen, Neurocrine Biosciences, United Therapeutics and Exelixis.

How do I contact Alnylam Pharmaceuticals' investor relations team?

Alnylam Pharmaceuticals' physical mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company's listed phone number is 617-551-8200 and its investor relations email address is [email protected] The official website for Alnylam Pharmaceuticals is www.alnylam.com.